Jul
12
Advocacy Committee Review of Prescription to OTC Switch for Norgestrel
OnTuesday, May 9th, NASPAG was one of 37 different organizations and/or individuals to speak at the Open Public Hearing session of the joint meeting of the Nonprescription Drugs Advisory Committee and the Obstetrics, Reproductive and Urologic Drugs Advisory Committee of the FDA. The Advisory Committee was assembled to review the application from HRA Pharma for a "prescription-to-OTC" switch for Norgestrel 0.075mg (Opill) as a progestin-only oral contraceptive. Speakers included several major medical societies, reproductive justice and advocacy organizations, and many youth who boldly shared their personal stories! Out of the 37 speakers, 35 spoke in strong support of the proposal.